Back to today’s briefing

Story perspectives

FDA Approves Spravato, Offering Hope for Depression Relief

1/28/2025

28 4

Summary

Story summary

The FDA has made a groundbreaking move by approving Spravato (esketamine) as a standalone treatment for adults battling treatment-resistant depression, offering new hope to many. In clinical trials, 22.5% of participants found relief within just four weeks. This pivotal decision paves the way for further exploration of innovative therapies, including atai's BPL-003 for alcohol use disorder.

1 of 1

Story summary

The FDA has made a groundbreaking move by approving Spravato (esketamine) as a standalone treatment for adults battling treatment-resistant depression, offering new hope to many. In clinical trials, 22.5% of participants found relief within just four weeks. This pivotal decision paves the way for further exploration of innovative therapies, including atai's BPL-003 for alcohol use disorder.